Your browser doesn't support javascript.
loading
Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma, Ying; Li, Jun; Wang, Huamin; Chiu, Yulun; Kingsley, Charles V; Fry, David; Delaney, Samantha N; Wei, Spencer C; Zhang, Jianhua; Maitra, Anirban; Yee, Cassian.
Afiliação
  • Ma Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston,
  • Li J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang H; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chiu Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston,
  • Kingsley CV; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fry D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston,
  • Delaney SN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston,
  • Wei SC; Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maitra A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston,
Gastroenterology ; 159(1): 306-319.e12, 2020 07.
Article em En | MEDLINE | ID: mdl-32179091
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático / Ligante OX40 / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Gastroenterology Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático / Ligante OX40 / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Gastroenterology Ano de publicação: 2020 Tipo de documento: Article